MedPath

pCLE For the Diagnosis Of Cancer in Unknown Bile Duct Stricture

Completed
Conditions
Cholangiocarcinoma
Bile Duct Inflammation
Registration Number
NCT01392274
Lead Sponsor
Mauna Kea Technologies
Brief Summary

This study will collect data from patients undergoing an ERCP procedure with probe-based Confocal Laser Endomicroscopy for suspicion of bile duct cancer. the objective is to evaluate the diagnostic performance of pCLE for the diagnosis of indeterminate biliary stricture when associated with other diagnostic information (standard ERCP and tissue sampling).

Detailed Description

This trial aims at evaluating the performance diagnosis of pCLE for the detection of bile duct cancer, in patients with indeterminate biliary stricture when associated with other diagnostic information.

The hypothesis is that ERCP with Cellvizio probe-based endomicroscopy improves differentiation of biliary and pancreatic duct lesions versus ERCP alone or ERCP with tissue sampling, by improving the sensitivity of detection and by providing a real-time diagnosis.

Direct measures of accuracy (sensitivity, specificity, etc.) in the differentiation of malignant versus benign biliary duct lesions will be compared for the combination of ERCP alone, endomicroscopy plus ERCP imaging, and ERCP plus endomicroscopy plus tissue sampling. These information will be reviewed retrospectively by a second physician.

These presumptive diagnoses will be compared against a 12-month follow-up confirmed histopathologic endpoint (an initially-benign pathologic diagnosis will be confirmed by a 12-month follow-up). Secondary objectives include collecting patient management recommendation. Yet, effective management recommendation is left as the discretion of the physician.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
121
Inclusion Criteria
  • Male or female > 18 years of age
  • Indicated for ERCP for indeterminate bile duct stricture
  • Referral patients with indeterminate biliary stricture coming in for first ERCP procedure at referral institution or
  • Patients who had previous non-diagnostic tissue sampling (brushing biopsies or EUS-FNA) taken during a previous ERCP or EUS-FNA for an indeterminate biliary stricture
  • Willing and able to comply with study procedures and provide written informed consent to participate in the study
Exclusion Criteria
  • Subjects for whom ERCP procedures are contraindicated
  • Known allergy to fluorescein dye
  • Patients suffering Primary Sclerosing Cholangitis or chronic pancreatitis.
  • Patients with post-transplant stricture
  • If female, pregnant based on a positive hCG serum or an in vitro diagnostic test result or breast-feeding

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Comparative histopathology-confirmed measures of Cellvizio endomicroscopy and ERCP accuracy in the differential diagnosis of suspicious l12 months

Evaluation of pCLE diagnostic performance for the diagnosis of indeterminate biliary stricture (ie. number of patients accurately diagnosed) when associated with other diagnostic information The following calculations will be conducted: sensitivity, specificity, positive and negative predictive values, Accuracy

Secondary Outcome Measures
NameTimeMethod
Comparative histopathology-confirmed measures of Cellvizio endomicroscopy and ERCP accuracy in the differential diagnosis of suspicious l12 months follow-up

Trial Locations

Locations (6)

University of Pittsburgh Medical Center

🇺🇸

Pittsburgh, Pennsylvania, United States

Virginia Mason Medical Center

🇺🇸

Seattle, Washington, United States

New York presbyterian Weill Cornell Medical center

🇺🇸

New york, New York, United States

Institut Paoli Calmettes

🇫🇷

Marseille, France

Policlinico Univertitario Agostino Gemelli

🇮🇹

Roma, Italy

Yale new Haven Hospital

🇺🇸

New Haven, Connecticut, United States

© Copyright 2025. All Rights Reserved by MedPath